Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Deffered Revenue: 2024-2025

Historic Non-Current Deffered Revenue for Prime Medicine (PRME) over the last 1 years, with Sep 2025 value amounting to $59.8 million.

  • Prime Medicine's Non-Current Deffered Revenue fell 4.61% to $59.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.8 million, marking a year-over-year decrease of 4.61%. This contributed to the annual value of $63.2 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Non-Current Deffered Revenue is $59.8 million, which was up 0.32% from $59.6 million recorded in Q2 2025.
  • Prime Medicine's Non-Current Deffered Revenue's 5-year high stood at $63.2 million during Q4 2024, with a 5-year trough of $59.6 million in Q2 2025.
  • In the last 2 years, Prime Medicine's Non-Current Deffered Revenue had a median value of $60.7 million in 2025 and averaged $61.2 million.
  • Data for Prime Medicine's Non-Current Deffered Revenue shows a maximum YoY dropped of 4.61% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Prime Medicine's Non-Current Deffered Revenue stood at $63.2 million in 2024, then decreased by 4.61% to $59.8 million in 2025.
  • Its last three reported values are $59.8 million in Q3 2025, $59.6 million for Q2 2025, and $60.7 million during Q1 2025.